Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04060199 |
|
Recruitment Status :
Completed
First Posted : August 19, 2019
Last Update Posted : October 27, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Duchenne Muscular Dystrophy | Drug: Viltolarsen Drug: Placebo | Phase 3 |
This is a Phase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of Viltolarsen in ambulant boys with Duchenne muscular dystrophy. Eligible patients with out-of-frame deletion mutations amenable to exon 53 skipping will be randomized to receive once weekly intravenous (IV) infusions of 80 mg/kg Viltolarsen or placebo for up to 48 weeks.
The study will enroll approximately 74 patients amenable to exon 53 skipping. Clinical efficacy will be assessed at regularly scheduled study visits, including functional tests such as Time to Stand Test (TTSTAND), Time to Run/Walk 10 Meters Test (TTRW), Six-minute Walk Test (6MWT), North Star Ambulatory Assessment (NSAA), Time to Climb 4 Steps Test (TTCLIMB) and Hand-held dynamometer (elbow extension, elbow flexion, knee extension and knee flexion on the dominant side only).
Safety will be assessed through the collection of adverse events (AEs), laboratory tests, electrocardiograms (ECGs), vital signs, and physical examinations throughout the study.
Blood samples will be taken periodically throughout the study to assess the pharmacokinetics of study drug.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 77 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD) |
| Actual Study Start Date : | April 14, 2020 |
| Actual Primary Completion Date : | October 19, 2023 |
| Actual Study Completion Date : | October 19, 2023 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Viltolarsen
Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 48 weeks.
|
Drug: Viltolarsen
IV infusion
Other Name: NS-065/NCNP-01 |
|
Placebo Comparator: Placebo
Patients amenable to exon 53 skipping will receive placebo intravenous (IV) infusions, weekly, for up to 48 weeks.
|
Drug: Placebo
IV infusion |
- TTSTAND [ Time Frame: baseline to 48 weeks of treatment ]Change in Time to Stand (TTSTAND)
- TTRW [ Time Frame: baseline to 48 weeks of treatment ]Change in Time to Run/Walk 10 Meters Test (TTRW)
- 6MWT [ Time Frame: baseline to 48 weeks of treatment ]Change in Six-minutes Walk Test (6MWT)
- NSAA [ Time Frame: baseline to 48 weeks of treatment ]
Change in North Star Ambulatory Assessment (NSAA)
The NSAA is a functional scale devised for use in ambulant children with Duchenne muscular dystrophy (DMD). It consists of 17 activities graded 0 (unable to perform), 1 (performs with modifications), 2 (normal movement). It assesses abilities necessary to remain ambulant that have been found to progressively deteriorate in untreated DMD patients, as well as in other muscular dystrophies such as Becker Muscular Dystrophy. NSAA Total Score ranges from 0 to 34, with a score of 34 implying normal function.
- TTCLIMB [ Time Frame: baseline to 48 weeks of treatment ]Change in Time to Climb 4 Steps Test (TTCLIMB)
- Hand-held dynamometer [ Time Frame: baseline to 48 weeks of treatment ]The force generated for each muscle strength (elbow extension, elbow flexion, knee extension, and knee flexion on the dominant side only) will be measured by Hand-held dynamometer.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 4 Years to 7 Years (Child) |
| Sexes Eligible for Study: | Male |
| Gender Based Eligibility: | Yes |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male ≥ 4 years and < 8 years of age
- Confirmed DMD mutation(s) in the dystrophin gene that is amenable to skipping of exon 53 to restore the dystrophin mRNA reading frame
- Able to walk independently without assistive devices
- TTSTAND < 10 seconds
- Stable dose of glucocorticoid (GC) for at least 3 months prior to study entry and is expected to remain on stable dose of GC treatment for the duration of the study
- Other inclusion criteria may apply
Exclusion Criteria:
- Current or history of chronic systemic fungal or viral infections
- Acute illness within 4 weeks prior to the first dose of study drug
- Evidence of symptomatic cardiomyopathy (Note: Asymptomatic cardiac abnormality on investigation would not be exclusionary)
- Allergy or hypersensitivity to the study drug or to any of its constituents
- Severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the investigator
- Previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety, make it unlikely that treatment and follow-up will be correctly completed or impair the assessment of study results, in the opinion of the investigator;
- Surgery within the 3 months prior to the first dose of study drug or surgery is planned for anytime during the duration of the study
- Participant has positive test results for hepatitis B antigen, hepatitis C antibody or human immunodeficiency virus (HIV)
- Currently taking any other investigational drug or has taken any other investigational drug within 3 months prior to the first dose of study drug or within 5 times the half-life of a medication, whichever is longer
- Previously enrolled in an interventional study of viltolarsen
- Currently taking any other exon skipping agent or has taken any other exon skipping agent within 3 months prior to the first dose of study drug
- Having taken any gene therapy
- Other exclusion criteria may apply
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04060199
Show 40 study locations
| Responsible Party: | NS Pharma, Inc. |
| ClinicalTrials.gov Identifier: | NCT04060199 |
| Other Study ID Numbers: |
NS-065/NCNP-01-301 |
| First Posted: | August 19, 2019 Key Record Dates |
| Last Update Posted: | October 27, 2023 |
| Last Verified: | October 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Muscular Dystrophies Muscular Dystrophy, Duchenne Muscular Disorders, Atrophic Muscular Diseases Musculoskeletal Diseases |
Neuromuscular Diseases Nervous System Diseases Genetic Diseases, Inborn Genetic Diseases, X-Linked |